Treatment of malaria tropica with a fixed combination of rifampicin, co-trimoxazole and isoniazid: A clinical study

Chemotherapy

Volumn 45, Issue 1, 1999, Pages 68-76

  Goerg, H ^a   Ochola, S A ^b,c   Goerg, R ^d  

^a Akado Devmt Women's Grp (NGO)   (Kenya)

^b Health Centre   (Kenya)

^c Homa Bay District Hospital   (Kenya)

^d Klinik Lowenstein   (Germany)

Author keywords

Co trimoxazole; Cotrifazid ; Isoniazid; Malaria tropica; Multidrug therapy; Rifampicin

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; COTRIFAZID; COTRIMOXAZOLE; FANSIDAR; ISONIAZID; RIFAMPICIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD SMEAR; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MIXTURE; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; ORAL DRUG ADMINISTRATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGE DISTRIBUTION; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; INFANT; ISONIAZID; KENYA; MALARIA, FALCIPARUM; RIFAMPIN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0032928326     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007167     Document Type: Article

References (38)

1. Ross R: On some peculiar pigmental cells found in two mosquitos fed on malaria. Br Med J 1997;ii:1786-1788.
2. Butler D: Time to put malaria control on the global agenda. Nature 1997;386:535-536.
3. Gallagher R: Global initiative takes shape slowly. Science 1997;277: 309.
4. Mockenhaupt FP, May J, Bienzle U, Meyer CG: Medikamentenresistente Malaria. Dtsch Med Wschr 1997;122:1293-1297.
5. Freerksen E, Kanthumkumva EW, Kholowa ARK: Malaria therapy and prophylaxis with Cotrifazid, a multiple complex combination consisting of rifampicin + isoniazid + sulfamethoxazole + trimethoprim. Chemotherapy 1995;41:396-398.
6. Freerksen E, Kanthumkumva EW, Kholowa ARK: Cotrifazid - An agent against malaria. Chemotherapy 1996;42:391-401.
7. Gardner MJ, Altman DG: Statistics with confidence - Confidence intervals and statistical guidelines. Br Med J 1989.
8. Assessment of therapeutic efficacy of antimalarial drugs for the complicated falciparum malaria in areas with intense transmission. WHO/ MAL/96.1077.
9. White NJ, Olliaro PL: Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malaria. Parasitol Today 1996;12:399-401.
10. Kremsner PG, Luty AJF, Graninger W: Combination chemotherapy for Plasmodium falciparum malaria. Parasitol Today 1997;13:167-168.
11. Merkli B, Richle L, Peters W: The inhibitory effect of a drug combination on the development of mefloquine resistance in P. berghei. Ann Trop Med Parasitol 1980;74:1-9.
12. Nosten F, ter Kuile F, Chongsuphajaisiddhi T, Luxemburger C, Webster HK, Edstein M, Phaipun L, Kyaw Lay Thew White NJ: Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet 1991;337:1140-1143.
13. von Seidlein L, Jaffar S, Pinder M, Haywood M, Snounou G, Gemperli B, Gathmann I, Royce C, Greenwood B: Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis 1997; 176:1113-1116.
14. Amukoye E, Winstanley PA, Watkins WM, Snow RW, Hatcher J, Mosobo M, Ngumbao E, Lowe B, Ton M, Minyiri G, Marsh K: Chloroproguanil-dapsone: Effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother 1997;41:2261-2264.
15. Sharp D: Promising antimalarial combination highlighted. Lancet 1996;348:1575.
16. White NJ, Krishna S: The treatment of malaria: Some considerations and limitations of the current methods of assessment. Trans Soc Trop Med Hyg 1989;83:767-777.
17. White NJ: Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997;41:1413-1422.
18. Panisko DN, Keystone JS: Treatment of malaria 1990. Drugs 1990; 39:160-189.
19. Freerksen E, Rosenfeld M, Spannuth G: New forms of multidrug therapy for the treatment of leprosy. Chemotherapy 1989;35:133-139.
20. Alger NE, Spira DT, Silverman PH: Inhibition of rodent malaria in mice by rifampicin. Nature 1970;227: 361-362.
21. Bloland PB, Redd STC, Kazembe P, Tembenu R, Wirima JJ, Campell CC: Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 1991;337:518-520.
22. Hansford CF, Hoyland J: An evaluation of co-trimoxazole in the treatment of Plasmodium falciparum malaria. S Afr Med J 1982;61:512-514.
23. Hutchinson DBA, Farquhar JA: Trimethoprim-sulphamethoxazole in the treatment of malaria, toxoplasmosis and pediculosis. Rev Infect Dis 1982;4:419-425.
24. Drews J: Grundlagen der Chemotherapie. Wien, Springer, 1979, pp 1-110.
25. Bhatia RS, Uppal R, Malhi R, Behera D, Jindal SK: Drug interaction between rifampicin and cotrimoxazole in patients with tuberculosis. Hum Exp Toxicol 1991;10:419-421.
26. Peters W, Lainson R, Shaw JJ, Robinson BL, Francaleao A: Potentiating action of rifampicin and isoniazid against Leishmania mexicana amanozensis. Lancet 1981;i:1122-1124.
27. Urbaschek R, Männel DA, Urbanczik R: Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release. Antimicrob Agents Chemother 1991;35:1666-1668.
28. Kwiatkowski D, Bate CAW, Scragg IG, Beattie P, Udalova I, Knight JC: The malarial fever response -Pathogenesis, polymorphism and prospects for intervention. Ann Trop Med Parasitol 1997;91:533-542.
29. Caro HN, Sheikh NA, Taverne J, Playfair JHL, Rademacher TW: Structural similarities among malaria toxins, insulin second messengers, and bacterial endotoxin. Infect Immun 1996;64:3438-3441.
30. Müller-Brundaler U, Dingfelder G, Urbanczik R: Improbability of selection for RIF resistance in Mycobacterium tuberculosis by accidental exposure during short-course therapy with Cotrifazid™. Chemotherapy 1997;43:451-452.
31. WHO Global Tuberculosis Programme, Geneva: Antituberculosis drug resistance in the world. WHO/ IUATLD Global Project on antituberculosis drug resistance surveillance 1994-1997. WHO/TB/ 97.229.
32. Smith TA, Charlwood JD, Kihonda J, Mwankuye S, Billingsley P, Meuwissen J, Lyimo E, Takken W, Teuscher T, Tanner M: Absence of seasonal variation in malaria parasitaemia in an area of extremely high, but seasonal transmission. Acta Trop 1993;54:55-72.
33. Viriyakosol S, Siripoon N, Petcharapirat C, Petcharapirat P, Jarra W, Thaithong S, Brownn KN, Snounou G: Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and its potential uses in epidemiologic studies. WHO Bull OMS 1995;73:85-95.
34. Snounou G, Beck H-P: The use of PCR-genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Parasitol Today 1998;14(11):462-467.
35. Al-Yaman F, Genton B, Reeder JC, Anders RE, Alpers MP: Evidence that recurrent Plasmodium falciparum infection is caused by recrudescence of resistant parasites. Am J Trop Med Hyg 1997;56:436-439.
36. Rathod PK, McErlean T, Pei-Chieh Lee: Variations in frequencies of drug resistance in Plasmodium falciparum: Proc Natl Acad Sci USA 1997;94:9389-9393.
37. Taylor RH, Walliker D, Read AF: Mixed-genotype infections of malaria parasites - within-host dynamics and transmission success of competing clones. Proc R Soc Lond B 1997; 264:927-935.
38. Babiker HA, Walliker D: Current views on the population structure of Plasmodium falciparum: Implications for control. Parasitol Today 1997;13:262-267.